Innovative Medicine Backed by the Power of Artificial Intelligence
BioXcel Therapeutics, Inc. a clinical-stage biopharmaceutical company utilizing artificial intelligence, or AI, to identify improved therapies in neuroscience and immuno-oncology.
Our neuroscience and immuno-oncology programs utilize our AI approach to drug development.
BXCL501
BXCL501 is an investigational, proprietary, orally dissolving, sublingual or buccal thin film formulation of dexmedetomidine designed for the treatment of agitation and substance abuse withdrawal symptoms.
BXCL701
BXCL701 is an investigational, orally administered, systemic innate immunity activator in development for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to check point inhibitors.
